Background To elucidate the extent of the compensatory role of endogenous atrial natriuretic peptide (ANP) in severe congestive heart failure (CHF), we examined the changes in hemodynamics and neuroendocrine and renal functions after incremental administration of an ANP antagonist, HS-142-1 (HS), in dogs with CHF.
Methods and Results We assessed the effects of HS on the suppression of plasma and urinary cGMP levels as a marker of endogenous ANP activity in dogs without CHF. Bolus injections of 0.3 and 1.0 mg/kg HS reduced plasma cGMP levels to 77% and 60% and urinary cGMP excretion to 78% and 61% of the relevant control levels, respectively. Then the study was performed in dogs with CHF induced by chronic rapid ventricular pacing, and the plasma ANP level was sixfold higher than that in the controls. Hemodynamic, hormonal, and renal variables were determined both before and after subsequent incremental administration (0.3, 1.0, and 3.0 mg/kg every 30 minutes) of HS. HS lowered the plasma and urinary cGMP levels dose dependently to 32% and 37% of the control levels, respectively. Mean arterial, pulmonary capillary wedge, and right atrial pressures and cardiac output did not change significantly. However, plasma renin activity, aldosterone level, and norepinephrine level increased rapidly to 226%, 179%, and 252% of the control values, respectively. Urine flow rate and urinary sodium excretion were significantly inhibited, with no concomitant change in glomerular filtration rate or renal plasma flow.
Conclusions These findings suggest that endogenous ANP contributes to the suppression of the activation of the reninaldosterone system and sympathetic nervous activity and body fluid retention but that the vasodilative action of this peptide is attenuated in advanced CHF. (Circulation. 1994;89:.2232-2240.)
Key Words * atrial natriuretic factor * guanosineheart failure, congestive P revious studies have shown that atrial natriuretic peptide (ANP) has potent vasorelaxant, diuretic, and natriuretic actions and shows neurohumoral effects that inhibit renin and aldosterone secretion. In congestive heart failure (CHF), the increase in ANP in the plasma may contribute to the compensatory regulation of hemodynamics, body fluid balance, and interaction of neurohumoral factors. Although the plasma ANP level remains elevated above basal values, the cardiac pressure increases, volume overload develops, and the renin-angiotensinaldosterone system and sympathetic nervous activity are significantly elevated during the progression of chronic CHF.1,2 In CHF, the response to ANP infusion is less sensitive with regard to the renal, hormonal, and hemodynamic changes compared with healthy control subjects.3-5 The compensatory effects of ANP appear to be attenuated in advanced CHF. We have shown previously that plasma levels of ANP and cGMP, an intracellular second messenger of ANP, become ele-vated with the progression of mild CHF. However, the plasma cGMP level reached a plateau despite the elevated level of ANP in chronic severe CHF. Therefore, we suggested that this is due to downregulation of guanylate cyclase (GC)-coupled ANP receptors in vascular beds.6 Several previous studies using antibodies against ANP have been performed to clarify the role of endogenous ANP activity in CHF.7,8 However, the exact role of endogenous ANP in CHF has not yet been determined, and whether its compensatory mechanism is actually attenuated in CHF remains unknown because no specific antagonist for ANP is available. We used a specific antagonist of GC-coupled ANP receptors, HS-142-1 (HS),9,10 to determine whether elevated endogenous ANP plays a compensatory role in advanced CHF. Hirata et all' used this ANP antagonist, HS, in DOC acetate (DOCA)-salt hypertensive rats and suggested that endogenous ANP is involved in the regulation of blood pressure and body fluid volume. In the present study, we examined the extent of the pathophysiological role of endogenous ANP in the regulation of the systemic hemodynamics, body fluid volume balance, and neurohumoral factors in the pacing-induced canine severe heart failure model system using HS in a dose-response study.
Methods

Animal Preparation
Conditioned mongrel dogs of both sexes, weighing 11 to 15 kg, were used for all experiments. Approval was obtained from the Animal Research Committee of Shiga University of Medical Science, and all dogs were preconditioned to the study environment for 4 weeks before experiments. The dogs were fasted overnight but allowed water ad libitum until the start of the experiment. Anesthesia was induced with pentobarbital sodium (25 mg/kg), with supplemental doses administered as necessary to maintain anesthesia. Dogs were intubated and ventilated with an Aika R-60 respirator. Through a left thoracotomy incision at the fourth intercostal space, the heart was exposed, the pericardium was opened, and two cardiac unipolar pacemaker leads (Matsuda M-23) were sutured onto the right ventricular apex. After the incision was closed, the leads were tunneled to the back and connected to the external pacemaker (model 540, Seamed). The left femoral vein was then exposed and a 7F Swan-Ganz thermodilution catheter (model T-047-03, Goodtec) was advanced into the pulmonary artery for measurement of right atrial pressure (RAP), mean pulmonary arterial pressure (MPAP), pulmonary capillary wedge pressure (PCWP), and cardiac output (CO). CO was assessed by the thermodilution technique in triplicate with 5 mL of ice-cold 0.9% saline injected into the right atrium. To evaluate the role of endogenous ANP in severe CHF, we divided the dogs with CHF induced by rapid pacing into two groups; one group (n=6) received HS and the other (n=5) received only saline as time controls. The dogs' bladders were catheterized as in study 1, and 45 minutes later a priming dose of 50 mg/kg creatinine and 8 mg/kg para-aminohippurate (PAH) dissolved in 10 mL saline solution was infused into the pulmonary artery over a 15-minute period according to the method of Riegger et a112 with some modifications. This was followed by a constant infusion (0.75 mL/min) of 1.0 mg. kg-' * min-t creatinine and 0.3 mg* kg`-l min`PAH throughout the experimental period. After a 60-minute equilibration period, when plasma concentrations were at a steady state, the bladder of each dog was completely emptied and flushed five times with sterile distilled water before the first of two clearance periods, each 30 minutes in duration, was begun. After stable basal hemodynamic records were obtained, HS was administered stepwise as a bolus at three doses of 0.3, 1.0, and 3.0 mg/kg dissolved in 20 mL saline or vehicle only (saline 20 mL) to exclude any temporal effects, injected at intervals of 30 minutes into the right atrium. Pressure measurements were repeated every 10 minutes for 90 minutes after injection. The collected pressure data included MAP, RAP, MPAP, and PCWP. CO was determined before and every 30 minutes after HS administration. Blood was drawn for analysis of plasma ANP level, cGMP concentration, PRA, aldosterone, and norepinephrine levels. Blood specimens were centrifuged at 40C, and the plasma was frozen at -300C until assay. After the HS injection, three additional 30-minute urine collections were made. Urine for analysis of urinary cGMP excretion was collected at the end of each clearance period, and urinary cGMP specimens were frozen at -30°C until assay.
Analysis of Blood and Urine Samples
Blood for the determination of plasma ANP, cGMP, PRA, aldosterone, and norepinephrine levels was collected from the pulmonary artery. Blood for ANP assay was collected in tubes containing aprotinin (500 kallikrein inhibitory units/mL) and EDTA (1 mg/mL) and immediately placed on ice. After centrifugation at 3000 rpm at 4°C, aliquots of plasma were measured by radioimmunoassay as previously described."3 Cross-reactivity was assumed to be 100% with dog ANP because the amino acid sequences are identical. The intraassay and interassay coefficients of variation were 6.3% and 9.6%, respectively. Plasma and urinary concentrations of cGMP were determined by radioimmunoassay with a commercial kit (Yamasa Syoyu Co Ltd),14 and intra-assay and interassay coefficients of variation were 2.4% and 8%, respectively. PRA was measured by radioimmunoassay (Gamma Coat Renin Kit, Clinical Assay). Plasma 51 .7±21.1 to 364.5+121.1 pg/mL (P<.01), and norepinephrine level from 162±37 to 539±100 pg/mL (P<.01). When the basal hemodynamic and hormonal data of all experimental animals were pooled, the differences between the HS and vehicle groups were not significant. cGMP Studies in CHF We investigated the changes in plasma and urinary cGMP concentrations as a marker of endogenous ANP activity. HS reduced plasma cGMP concentration dose dependently from 33.7+6.5 pmol/mL before injection to 10.2±+1.4 pmol/mL 90 minutes after injection (P<.001).
After injection of HS at 0.3 and 1.0 mg/kg, the plasma cGMP value was reduced to 67.6% and 44.5% of the basal value, respectively, and at the maximal dose, HS lowered the cGMP concentration to 32.0% (Fig 1) . Urinary cGMP excretion was also inhibited significantly, from 5129±+1542 to 1950±665 pmol/mL, dose dependently (P<.01). Percent changes in urinary cGMP excretion were reduced to 81.1% of the average basal value by 0.3 mg/kg HS, to 48 .4% by 1.0 mg/kg HS, and to 37.3% by 3.0 mg/kg HS (Fig 2) . Hemodynamic Changes in CHF  Fig 3 shows 
Discussion
To elucidate the pathophysiological roles of endogenous ANP in severe CHF, we administered the antagonist of GC-coupled ANP receptors, HS, to dogs with heart failure induced by rapid ventricular pacing. We investigated the extent to which endogenous ANP actually contributes to the regulation of the hemodynamic, neurohumoral function, and body fluid balance in severe CHF by HS administration. HS dose dependently lowered both plasma and urinary cGMP concentrations while increasing PRA and aldosterone and norepinephrine levels. Renal excretion of sodium and water was reduced, with no associated changes in GFR or RPF, although cardiac hemodynamics remained unchanged throughout the experimental period. Plasma and urinary cGMP levels have been demonstrated to serve as biological markers of endogenous ANP activity.15-18 Although cGMP is produced by the activation of two different isoenzyme forms of GC, soluble and particulate GC, ANP is well known to interact specifically only with particulate GC. Conversely, nitric oxide (NO) activates soluble GC and in turn increases the cGMP levels in endothelial and vascular smooth muscle cells. The NO system may alter the renin-angiotensin-aldosterone system and sodium excretion.1920 HS specifically blocks the actions of ANP without inhibiting other cGMP-linked substances such as sodium nitroprusside and acetylcholine, which are known to activate soluble GC and stimulate NO production. HS does not inhibit the sodium nitroprusside-induced accumulation of cGMP observed in porcine kidney epithelial LLC-PK1 cells and rabbit aortic rings10,21 or prevent the vasodilative response to acetylcholine observed in isolated rat renal artery."1 Thus, HS specifically blocks ANP-induced cGMP production through specific blockade of the particulate GC-linked receptor. The U-cGMP indicates urinary cGMP excretion; U-V, urine flow rate; U-Na, urinary sodium excretion; GFR, glomerular filtration rate; RPF, renal plasma flow; and FF, filtration fraction. After two 30-minute basal clearances were obtained, HS 0. experimental animals used and basal diseases studied. Previously, we reported that the effect of attenuation of endogenous ANP activity on hemodynamics observed in patients with severe chronic CHF may be due to the downregulation of ANP receptors in the vascular beds.6,14 In addition, the mechanism of the reduction in vasodilative action of endogenous ANP in this study may be related to a defect in intracellular mechanisms other than those involved in the production of cGMP, because the hemodynamics were not altered significantly when the plasma cGMP level was reduced below the basal level.32526 However, there is an alternative possibility that the reduced level of plasma cGMP does not originate mainly from the smooth muscle but rather from the vascular endothelium. Porter et a127 recently reported that the potency of ANP in the induction of cGMP production is even higher in endothelial than in smooth muscle cells. Therefore, inhibition of the ANP receptor in smooth muscle may not be sufficient to elicit significant hemodynamic changes. Plasma Hormonal Changes
In study 2, the plasma ANP concentrations were significantly elevated after HS administration. Although HS very selectively blocks the biologically active receptor (B-receptor) that is coupled to GC, HS does not affect the binding of ANP to the metabolic clearance receptor, which lacks GC activity. 10, 2829 The attenuation of ANP metabolism may be due to impaired internalization of ANP-receptor complexes in CHF30-32 However, the increase in plasma ANP levels observed in the present study may be a consequence of HS displacing ANP from the B-receptor or blocking its binding to the B-receptor, since we found that HS also tended to induce an increase in plasma ANP levels in dogs without CHF in study 1. We observed rapid and marked elevation of PRA, aldosterone, and norepinephrine levels despite the lack of overall deterioration in systemic hemodynamics. This is, to the best of our knowledge, the first demonstration of a significant role of endogenous ANP in counteracting these vasoconstrictive/antidiuretic hormones in CHF. In the present study, PRA increased to 226% of the control level when the cGMP level had decreased to 32%. Several previous studies have shown that exogenous ANP, administered intravenously, suppresses renin secretion, despite a sustained decrease in arterial pressure.3'5'33'34 However, whether endogenous ANP has an inhibitory effect on renin release remains controversial. After administration of ANP antiserum in a normal rat model, Naruse et a135 observed an elevation in PRA, whereas Rudd et a136 reported no change in PRA. In the present study, we observed a significant elevation of the already activated PRA compared with the prepacing values when endogenous ANP activity was suppressed by HS. Although ANP-mediated renin inhibition may involve a macula densa mechanism, the results of the present study do not allow us to distinguish between this and a direct receptor-mediated mechanism.4 '37 Secretion of aldosterone is known to be inhibited by exogenous ANP, both in vivo and in vitro.38M39 In the present study, plasma aldosterone level increased to 179% of the control level; plasma angiotensin II level also increased, but not significantly (data not shown). We consider the increase in aldosterone secretion not to be stimulated by angiotensin II but rather to be a result of the release from direct ANP-mediated inhibition. Oda et aW40 demonstrated a positive correlation between the restoration of ANP-induced inhibition of aldosterone production and the reduction of intracellular cGMP level by administration of HS to adrenal glomerulosa cells. Our findings in the present study indi- ANP, may play a pathophysiological role in CHF. Although two similar membrane-bound GCs (GC-A and GC-B) are known to be natriuretic peptide receptors, GC-A is an ANP and BNP receptor, whereas GC-B is a specific receptor for the C-type natriuretic peptide (CNP).56,57 HS was equally effective in inhibiting the increase in cGMP production stimulated by BNP, CNP, or ANP.21.58 HS shows almost equal antagonistic activity on GC-A and GC-B. In the present study, we could not measure the plasma concentrations of either BNP or CNP, and therefore, we cannot exclude the possibility that our findings are due to inhibition of these peptides. Further investigation is required to determine to what extent HS inhibits the effects of BNP or CNP in CHE.
In summary, the increment in endogenous ANP observed in severe CHF actually suppresses the activation of the renin-aldosterone system and sympathetic nervous activity and inhibits the reabsorption of water and sodium without inducing changes in GFR or RPF. However, endogenous ANP exerts no significant hemodynamic effect through its vasodilative activity.
